ID: ALA3233837

Max Phase: Preclinical

Molecular Formula: C23H21N5O2

Molecular Weight: 399.45

Molecule Type: Small molecule

Representations

Canonical SMILES:  N#C[C@@H]1CCCN1C(=O)CNC(=O)c1ccnc2cc(Nc3ccccc3)ccc12

Standard InChI:  InChI=1S/C23H21N5O2/c24-14-18-7-4-12-28(18)22(29)15-26-23(30)20-10-11-25-21-13-17(8-9-19(20)21)27-16-5-2-1-3-6-16/h1-3,5-6,8-11,13,18,27H,4,7,12,15H2,(H,26,30)/t18-/m0/s1

Standard InChI Key:  JYZCEZUNDURZDS-SFHVURJKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 399.45

Molecular Weight (Monoisotopic): 399.1695

AlogP: 3.22

#Rotatable Bonds: 5

Polar Surface Area: 98.12

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 4.19

CX LogP: 1.92

CX LogD: 1.92

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.69

Np Likeness Score: -1.32

References

1. Jansen K, Heirbaut L, Verkerk R, Cheng JD, Joossens J, Cos P, Maes L, Lambeir AM, De Meester I, Augustyns K, Van der Veken P..  (2014)  Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP).,  57  (7): [PMID:24617858] [10.1021/jm500031w]

2.  (2016)  FAP inhibitors, 

Source

Source(2):

• Scientific Literature
• BindingDB Database